AADACL3 Inhibitors
AADACL3 inhibitors are a diverse group of chemical compounds that, through their interaction with various lipid metabolism pathways, indirectly lead to the diminished functional activity of arylacetamide deacetylase-like 3 (AADACL3). THL, a lipase inhibitor, through its action in the gastrointestinal tract, reduces the breakdown and subsequent availability of dietary fats, potentially affecting the lipid substrates that AADACL3 acts upon. Similarly, Eicosatetraynoic Acid (ETYA), by competing with arachidonic acid, can alter eicosanoid synthesis, possibly affecting the lipid signaling milieu that AADACL3 is part of. Triacsin C and RHC-80267 both target enzymes that are upstream of AADACL3, reducing the levels of acyl-CoA and diacylglycerols, respectively, which could be crucial for AADACL3's role in lipid processing. PD 98059 and ML355 modulate the MAPK/ERK pathway and 12-lipoxygenase activity, respectively, which may have downstream effects on the regulation of AADACL3's activity in the cell.
Continuing with the theme of lipid metabolism interference, Zoxamide, an acetyl-CoA carboxylase inhibitor, may reduce malonyl-CoA levels, thereby potentially affecting the fatty acid substrate availability for AADACL3. A23187 and Tipifarnib, both farnesyltransferase inhibitors, could impact the post-translational modification of proteins that regulate or interact with AADACL3, leading to a decrease in the enzyme's activity. Cerulenin, by inhibiting fatty acid synthase, could lower the pool of fatty acids and diacylglycerols, potentially diminishing AADACL3 activity. Lastly, Tunicamycin may disrupt AADACL3 function by inhibiting its glycosylation, which is necessary for its stability or activity. Collectively, these inhibitors, by affecting different aspects of lipid metabolism and enzyme regulation, contribute to the indirect inhibition of AADACL3's function within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
THL is known as a lipase inhibitor which works by covalently binding to the serine residue of gastric and pancreatic lipases in the lumen of the gastrointestinal tract, thus preventing the hydrolysis of dietary fats. As AADACL3 is a lipid-related enzyme, orlistat could theoretically diminish its activity by altering lipid metabolism and availability. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
This compound is a potent inhibitor of long-chain acyl-CoA synthetase, an enzyme critical for the conversion of free fatty acids into fatty acyl-CoA, the form used for lipid synthesis and degradation. Diminishing acyl-CoA levels could indirectly reduce the available substrate for AADACL3 enzyme function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which in turn blocks the MAPK/ERK pathway. The MAPK/ERK pathway is implicated in various cellular processes, including the regulation of enzymes involved in lipid metabolism. Inhibition of this pathway could indirectly reduce AADACL3 activity by altering regulatory networks that control enzyme activity levels, including those related to lipid metabolism where AADACL3 may play a role. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
This compound is a farnesyltransferase inhibitor that can indirectly affect AADACL3 by disrupting the prenylation and proper functioning of various proteins, potentially including those that regulate AADACL3's activity or substrate availability. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin is an inhibitor of fatty acid synthase which could decrease the availability of endogenous fatty acids, potentially leading to a reduction in AADACL3 enzymatic activity if these fatty acids serve as substrates or cofactors for AADACL3. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
As an inhibitor of farnesyltransferase, Tipifarnib may alter the post-translational modification of proteins that interact with or regulate AADACL3, potentially leading to decreased AADACL3 functional activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which may affect AADACL3 if it undergoes glycosylation for its stability or activity. By inhibiting this process, AADACL3's structure and function could be indirectly compromised. | ||||||